OncoMed Pharmaceuticals

OncoMed is a clinical-stage biopharmaceutical company focused on discovering and developing therapeutic candidates directed to fundamental biologic pathways and targets thought to drive cancer’s growth, resistance, recurrence, and metastasis. The company offers several therapeutic candidates specifically targeting cancer stem cell pathways and it has an emerging pipeline of immuno-oncology therapeutic candidates that aim to bolster immune system recognition of cancer cells and/or suppress immune system evasion mechanisms.

Employee Rating

3.7More
TypeSubsidiary
Parent CompanyMereo BioPharma
HQRedwood City, CA, US
Founded2004
Websiteoncomed.com
Cybersecurity ratingBMore
OncoMed Pharmaceuticals was founded in 2004 and is headquartered in Redwood City, CA, US

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at OncoMed Pharmaceuticals

Austin Gurney

Austin Gurney

Senior Vice President, Molecular and Cellular Biology
Jill Henrich

Jill Henrich

Vice President, Regulatory Affairs
Alicia J. Hager

Alicia J. Hager

Vice President, General Counsel
Tim Hoey

Tim Hoey

Senior Vice President, Cancer Biology
Show more

OncoMed Pharmaceuticals Office Locations

OncoMed Pharmaceuticals has an office in Redwood City
Redwood City, CA, US (HQ)
800 Chesapeake Dr
Show all (1)

OncoMed Pharmaceuticals Financials and Metrics

Summary Metrics

Founding Date

2004

Total Funding

$210.2 m

Investors

In total, OncoMed Pharmaceuticals had raised $210.2 m. OncoMed Pharmaceuticals is a subsidiary of Mereo BioPharma

OncoMed Pharmaceuticals Revenue

OncoMed Pharmaceuticals's revenue was reported to be $44.42 m in FY, 2018
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

37.8m39.6m25.9m25.2m38.2m44.4m

General and administrative expense

11.6m13.8m18.6m18.8m16.8m18.2m

R&D expense

50.0m76.4m92.9m109.7m59.8m34.4m

Operating expense total

61.7m90.2m111.5m128.5m79.1m54.5m
Quarterly
USDQ2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Revenue

2.9m12.9m6.0m6.0m19.0m9.7m4.7m4.7m6.4m6.7m5.9m6.2m6.2m5.1m7.8m6.9m19.5m

General and administrative expense

2.0m3.2m3.2m3.4m3.5m4.8m4.3m4.5m5.2m4.8m4.5m5.0m4.1m3.9m5.4m3.7m3.7m

R&D expense

10.5m13.1m16.7m18.2m21.0m19.4m22.0m24.7m28.4m29.7m27.4m24.0m15.1m12.2m8.4m8.1m10.0m

Operating expense total

12.4m16.3m19.9m21.6m24.5m24.2m26.3m29.2m33.6m34.5m31.9m29.0m21.6m16.1m13.8m11.8m13.7m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

208.9m28.1m38.4m37.0m13.3m9.7m

Accounts Receivable

70.7m405.0k3.0m

Prepaid Expenses

2.5m1.7m3.3m1.7m1.9m

Inventories

USDQ2, 2013

Financial Leverage

-0.4 x
Show all financial metrics

OncoMed Pharmaceuticals Cybersecurity Score

Cybersecurity ratingPremium dataset

B

84/100

SecurityScorecard logo

OncoMed Pharmaceuticals Online and Social Media Presence

Embed Graph

OncoMed Pharmaceuticals News and Updates

Mereo BioPharma Group plc ("Mereo" or the "Company" or the "Group") Merger Update: Acquisition of OncoMed Pharmaceuticals, Inc. ("OncoMed") – Result of OncoMed Stockholder Meeting

LONDON, April 18, 2019 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (AIM: MPH), a clinical stage, UK-based, biopharmaceutical company focused on rare diseases, announces today that stockholders of OncoMed (NASDAQ: OMED) have approved the transactions contemplated by the merger agreement dated 5 D…

Proposed Combination of Mereo BioPharma and OncoMed Pharmaceuticals

To be effected by an all-stock transaction plus issuance of Contingent Value Rights (“CVRs”); completion expected H1 2019

OncoMed Pharmaceuticals Frequently Asked Questions

  • When was OncoMed Pharmaceuticals founded?

    OncoMed Pharmaceuticals was founded in 2004.

  • Who are OncoMed Pharmaceuticals key executives?

    OncoMed Pharmaceuticals's key executives are Austin Gurney, Jill Henrich and Alicia J. Hager.

  • How many employees does OncoMed Pharmaceuticals have?

    OncoMed Pharmaceuticals has 22 employees.

  • What is OncoMed Pharmaceuticals revenue?

    Latest OncoMed Pharmaceuticals annual revenue is $44.4 m.

  • What is OncoMed Pharmaceuticals revenue per employee?

    Latest OncoMed Pharmaceuticals revenue per employee is $2 m.

  • Who are OncoMed Pharmaceuticals competitors?

    Competitors of OncoMed Pharmaceuticals include OBI Pharma, Mirati Therapeutics and Spectrum Pharmaceuticals.

  • Where is OncoMed Pharmaceuticals headquarters?

    OncoMed Pharmaceuticals headquarters is located at 800 Chesapeake Dr, Redwood City.

  • Where are OncoMed Pharmaceuticals offices?

    OncoMed Pharmaceuticals has an office in Redwood City.

  • How many offices does OncoMed Pharmaceuticals have?

    OncoMed Pharmaceuticals has 1 office.